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OBJECTIVES: Diabetes mellitus is responsible for a huge burden of disease. Our 
objective was to estimate the direct health-care costs of patients with diabetes in 
Hungary. METHODS: Real-world data were retreived from the National Health 
Insurance Fund database. Diabetic patients were deﬁ ned as persons who ﬁ lled in a 
prescription of oral antidiabetics (OAD) or insulin in Q3-Q4 2007. Study population 
was divided into two groups depending on whether they were hospitalized for major 
complications of diabetes in 2007–2008. Patients without hospitalization were further 
divided into three subgroups according to the use of drugs (only OAD, only insulin, 
OAD and insulin). In all subgroups, we estimated health-care costs for each cost item 
by age group in the whole study group and among those who actually used a particular 
service. Additionally, we took samples of patients who were hospitalized for speciﬁ c 
complications, and estimated health-care costs for the ﬁ rst and second year after the 
occurrence of the complication. Hungarian Forint values were converted to Euros by 
employing the 2008 GDP speciﬁ c PPP exchange rate (1c = 157.64HUF). RESULTS: 
Mean health-care cost of 521,545 diabetic patients was c2125 in 2008. It was c4016 
for those with hospitalization for complications, c1533 for OAD users without com-
plications, and c2847 for insulin users without complications. Fifty-three percent of 
the total cost covered drug treatment and 27% acute hospital treatment; 26% of the 
total drug cost was spent on OADs and on insulin. CONCLUSIONS: Health-care cost 
of diabetes is already high in Hungary, especially care for its complications. Public 
health-care cost of diabetes exceeds 0.65% of GDP and 13% of total direct public 
health-care expenditure. Considering the burden of disease that manifests in premature 
mortality, reduction in QoL, and high cost, and the epidemiological trends, diabetes 
mellitus should be a public health priority in Hungary.
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BACKGROUND: Recent research suggests that direct medical costs and quality of 
life in diabetes depends on number of diabetes-related complications. OBJECTIVES: 
To analyze relationships of quality of life and medical costs with clinical characteristics 
of diabetes mellitus patients. METHODS: A retrospective longitudinal cost of care 
study was conducted; type 1 and 2 diabetic patients accessing at two hospitals in the 
north-east area of Italy were recruited between October 2008 and March 2009. At 
enrollment data on demographic, clinical status and QoL (EQ-5D) were collected. 
Information on costs occurring during the previous 2 years was obtained from a chart 
review: hospitalizations, specialist medical visits, diagnostic examinations, drugs, and 
the main clinical parameters. Costs were quantiﬁ ed from the National Health Service 
(NHS), by applying tariffs and prices valid in 2009. Data were analyzed with a mul-
tivariable linear regression model. RESULTS: A total of 411 valid patients (mean + 
SD age = 64.1 + 12.7, 56.5% male) were enrolled: 15.9% had type 1, 83.4% type 2 
diabetes, and 0.7% had other type of diabetes. Costs were on average c234.36/patient-
month; hospitalization accounted for the greatest proportion of costs (58.5%), fol-
lowed by pharmacological therapies (32.6%) and diagnostic exams (8.9%). With 
EQ-5D: VAS was on average + SD = 67.74 ± 16.71. Both Costs and HRQoL showed 
a linear-positive (costs) and -negative (HRQoL) relationship with number of diabetes-
related complications (diabetic retinopathy, diabetic nephropathy, diabetic neuropa-
thy, ischemic cardiopathy, vascular diseases, and diabetic foot), adjusting for age and 
gender and type of diabetes. On the contrast, no relationship was found with type of 
complications. CONCLUSIONS: Long-term complications carry a considerable 
impact on medical cost and HRQoL. Although apparently costly, strategies aimed to 
optimize the prevention of the onset of diabetic complications should be considered 
as a potential investment to gain health and reduce costs in the long run.
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OBJECTIVES: The painful diabetic peripheral neuropathy (DPN) is the most common 
complication of diabetes. Despite the prevalence of painful DPN and its potential risk 
of foot ulcer and amputation, there has been no study about painful DPN on economic 
burden in Korea. This study was conducted to assess the patient-level economic burden 
among subjects with painful DPN. METHODS: A cross-sectional multicenter study 
was performed using a standardized questionnaire, to estimate recent 3-month health-
care and non-health-care cost, and productivity loss of diabetic patients. a total of 
4000 patients were recruited from 40 hospitals between December 2009 and May 
2010. Cost items mainly included health-care cost such as outpatient, pharmacy, 
inpatient, and oriental medicine; non-health-care cost such as trafﬁ c expenses, nursing 
cost, complementary, and alternative medicine. Cost included insurance-covered cost 
as well as patient’s out-of-pocket expenses during 3 months. To estimate productivity 
loss due to morbidity, days away from work due to painful DPN were also investi-
gated. RESULTS: Among 2681 diabetic patients completed questionnaire (response 
rate = 67.0 %), 26.3% (n = 706) had painful DPN. Numbers of outpatient visit within 
3 months were higher in patients with painful DPN compared to those in patients 
without painful DPN, 3.79 ± 2.83 and 3.25 ± 2.36, respectively (P < 0.01). Total costs 
over 3 months were also higher in patients with painful DPN than in those without 
painful DPN (1,049,477 ± 1,549,446 and 721,933 ± 1,394,970 KRW, respectively, 
P < 0.01); Median costs were higher among patients with painful DPN (656,585 vs. 
421,668 KRW). Within 3 months, 8.2% and 43.5% of patients with painful DPN 
had been away from work and reported the decreased work productivity, respectively. 
CONCLUSIONS: Painful DPN increased health-care cost and decreased work pro-
ductivity of diabetic patients in Korea.
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OBJECTIVES: As in so many other countries, diabetes is one of the largest health 
problems faced by Portugal. Up to now, there have been no “cost of illness” studies for 
diabetes in Portugal. This paper provides a contribution to ﬁ ll that gap by estimating 
the indirect costs of illness, more speciﬁ cally the output loss due to short- and long-term 
disability attributable to diabetes in Portugal. METHODS: The estimates are based on 
the microdata of the 4th National Health Survey conducted in 2005/2006. An employ-
ment logit is estimated with covariates including age, gender, education levels, and 
regional dummies as well as a dummy for diabetes and dummies for other relevant 
health conditions for all people in the survey with ages between 20 and 74. a comparison 
of the baseline labor market participation/employment estimates and model predictions 
assuming zero diabetes prevalence provides the estimates for the labor market impact 
of diabetes. The estimates are speciﬁ ed by age groups and gender. At this point, the 
analysis uses microdata from the Labor Ministry, covering about 3 million workers, to 
estimate gross wages and employer Social Security contributions by age and gender, 
allowing us to use the human capital approach to put a value on the diabetes-induced 
labor market nonparticipation. RESULTS: The nonemployment estimates generated by 
the logit-based methodology are that diabetes reduces employment by 22,150 in a 4.6 
million demographic group. The corresponding output loss is estimated to have been 
c324 million. CONCLUSIONS: The output loss is one of the main costs of diabetes in 
Portugal. Its amount is four times larger than the available estimates for diabetes’ 
attributable inpatient care in National Health Service hospitals.
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OBJECTIVES: Diabetes is one of that chronic diseases in which the increase of the costs 
cause ﬁ nancial problems for the National Health Insurance Fund in Hungary. Aim of 
the study is the examination of it in a 5-year period from 2003 to 2008. METHODS: 
The number of diabetic patients, the type of treatment services, the ﬁ nancial support, 
and the costs were analyzed. Data were derived from the National Health Insurance 
Fund Administration. RESULTS: Measuring by the medical ID, the numbers of patient 
increased by 34% during 5 years. The numbers of case increased in the outpatient 
services by 14% (from 213,790 to 243,960). The numbers of the hospital treatment day 
decreased by 5% (3,342,857; 3,168,263) The day off work due to sickness and the cost 
of it increased by 345% (from 8275c to 36,860c). While ﬁ nancial support of devices 
for the measurement of blood sugar increased by 93% c4900 to c9400 and support of 
insulin treatment increased 111%, than the increase of the number of insulin-treated 
patients was only 46%, 91,920 (2003) and 134,617 (2008). Similarities were seen in 
numbers (40%) and in costs (94%) in the noninsulin-treated patients from 195,662 to 
274,886 and from c7900 to c15,300. The total change in ﬁ nancial support was 72%. 
CONCLUSIONS: Increase in the number of diabetic patients was seen during this 5-year 
period. The increase of the number in outpatient services was higher than in inpatient 
services. The decrease in numbers of hospital bed could explain it. The economic crisis 
could cause the growing in the numbers of day off work. The increase in the medical 
ﬁ nancial support compared to the number of patients had to be mentioned, because it 
could be caused by enhancement in the administration of the innovative medical prod-
ucts. Basic strategy should be found against health cost explosion.
PDB29
COST OF DIABETES MELLITUS TYPE 1 AND 2 STUDIES IN COUNTRIES 
OF CENTRAL AND EASTERN EUROPE—A SYSTEMATIC REVIEW OF 
THE LITARATURE
Kawalec P1, Czech M2
1Jagiellonian University, Kraków, Poland; 2Novo Nordisk Pharma Sp z.o.o., Warsaw, Poland
OBJECTIVES: Despite the rapid development of pharmacoeconomics and outcomes 
research in new countries joining European Union (EU), there is still scarcity of cost 
of illness studies compared to old EU members. The aim of the study was to review 
all studies concerning costs of diabetes type 1 and 2 and its complications in old and 
new EU members. The following countries were taken into account: Slovenia, Poland, 
Czech Republic, Hungary, Slovakia, Bulgaria, Romania, Lithuania, Latvia, and 
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Estonia—as new EU members and remaining EU countries as old members. 
METHODS: A systematic review of the following databases was conducted: Medline 
(PubMed), Embase, Cochrane. In addition, NICE, INAHTA, HTAI, and ISPOR Inter-
net pages were searched. The following key words were used: cost of illness diabetes 
with name of a country or burden of illness diabetes with name of a country. Studies’ 
design, methods, scope, and results were compared. Direct and indirect costs were 
considered separately, detailed costs’ categories and costs related to complications 
were distinguished. Perspectives, time frames were taken into consideration and 
current exchange rates for communication purposes were used. Studies published in 
English language were included. RESULTS: Only 12 studies concerning cost of dia-
betes type 1 and 2 and their complications in new EU countries were found as com-
pared to 67 from old EU members. On the side of new EU members, one study was 
found in Lithuania and Bulgaria, three in Czech Republic, and seven in Poland. In old 
EU countries, one study was found in Luxembourg and Greece, two in Austria, 
Belgium, Finland, and Ireland, three in France and The Netherlands, seven in Spain 
and Italy, eight in Great Britain, 13 in Sweden, and 16 in Germany. CONCLUSIONS: 
Results of this review revealed the necessity of carrying out more studies concerning 
cost of diabetes and its complications in new EU members.
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OBJECTIVES: Diabetic foot (DF) is one of the most important complications of 
diabetes mellitus. If not treated properly, diabetic foot may often lead to infections, 
amputations, and ﬁ nally to disability. Unfortunately, only few studies of the cost of 
diabetic foot treatment were available in Russia; most of the studies were completed 
about 10 years ago. We suggested that the data of earlier studies could not reﬂ ect 
present level of expenditures. Therefore, we launched a study of the cost of diabetic 
foot treatment in present conditions. METHODS: We have analyzed the data of 146 
inpatients treated in diabetic foot department at Scientiﬁ c Centre for Endocrinology 
(Moscow, Russia) in 2008–2009. The patients’ data were input into a specially 
designed medical information system. The patients were sorted into three main groups: 
1) diabetic polyneuropathy without diabetic foot (N = 37); 2) diabetic foot without 
amputations (N = 58); and 3) patients with amputations due to diabetic foot (N = 
51). To calculate the total cost of DF treatment, costs of diagnostic procedures, medi-
cines, bandaging, surgical operations, and staying in the hospital were summed. 
RESULTS: Mean cost of treatment of one DF patient was equal to 81,700 rubles 
(US$2645), which is about 30% higher than previously reported ﬁ gures. It is mainly 
due to larger introduction of recombinant insulins into routine treatment of diabetic 
patients. Mean cost of treatment of DF patients with amputations was signiﬁ cantly 
higher than in those without amputations, mostly due to additional costs of surgical 
treatment and longer stay in a hospital. Moreover, the mean cost of medicines for DF 
patients with amputations was almost twice higher than for DF patients without 
amputations. CONCLUSIONS: The cost of diabetic foot treatment in Russia increased 
approximately 30% during last 10 years. The results will be used to assess cost-
effectiveness of various drug treatments of diabetic foot.
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OBJECTIVES: Damage to the recurrent laryngeal nerve (RLN) is one of the principal 
reasons for malpractice claims against surgeons in otorhinolaryngology. Intraoperative 
neuromonitoring (IONM), facilitating the identiﬁ cation of RLN, has been demon-
strated to be a valid technical support to reduce intraoperative risks. Aim of this study 
was to evaluate the additional hospitalization costs for thyroidectomy due to IONM, 
against the mentioned clinical and administrative advantages. METHODS: The study 
was performed in an experienced Italian University Hospital, in which the learning 
curve for this technology is considered completed. Through a microcosting approach, 
the thyroidectomy patient care process (with and without IONM) was costed consider-
ing direct costs only (staff time, consumables, equipment, drugs, operating room, and 
general expenses) and according to the hospital perspective. Unit costs were collected 
from hospital accounting and standard tariff lists. a differential analysis was per-
formed to highlight additional resource consumption (time effort, consumables, tech-
nology equipment) due to IONM usage. To assess the impact of the technology on 
hospital management, three scenarios were considered: 1) traditional thyroidectomy; 
2) thyroidectomy with IONM in a high-volume setting (ﬁ ve procedures per week); 
and 3) thyroidectomy with IONM in a low-volume setting (one procedure per week). 
RESULTS: The cost for hospitalization for a traditional thyroidectomy was c3471. If 
IONM is used, costs increase as follows: +7% in a high-volume setting (c3713) and 
+9% in a low-volume setting (c3770). IONM therefore represents only the 6% to 7% 
of the total hospitalization costs. CONCLUSIONS: IONM for thyroid surgery could 
reduce the risk of RLN damages and of the consequent malpractice claims against a 
very low impact on hospital budget, accounting only for the 7% of the hospitalization 
costs for a thyroidectomy. Considering that IONM could be useful in all surgical 
procedures where nerves are at risk, the economic impact could be even lower due to 
a higher level of usage of the equipment.
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OBJECTIVES: The available T2DM (type 2 diabetes mellitus) therapies attend with 
weight gain, which affects for the disease outcomes in a very extent way. Weight gain 
could worsen the long-term effect of insulin therapy (increased risk of insulin resis-
tance, hypertension, dyslipidemia), which inﬂ uences the total treatment cost. Long-
acting insulin analogue therapies (insulin detemir and glargine) offer improved 
pharmacokinetic and pharmacodynamic properties compared to regular human 
insulin. In a previous meta-analysis, detemir caused signiﬁ cant lower weight gain than 
glargine (−2.04 kg after 6 months therapy). Our research aimed to determine the 
effects of weight gain and calculate the total treatment cost. METHODS: On the basis 
of a systematic literature review, we found many consequences, which could be obesity 
related. Because of its important effect and bride prevalence, we analyzed the CHD 
(coronary heart disease) risk changes related to the weight gain. We modiﬁ ed the 10 
years risk—calculated with the UKPDS risk engine—with the effects of the weight gain 
published in a meta-analysis. We aggregated the differences in natural outcomes 
(number of avoided fatal and nonfatal events) and in monetary unit, based on real-
world data. RESULTS: In our analysis, we assessed that insulin detemir-treated 
patients—due to the favorable features regarding weight gain compared to glargine—
experience smaller (cca 2%) CHD risks. It means, for the current treated Hungarian 
population, that there are 223 coronary (158 fatal of this) events avoidable in 10 years 
horizon using detemir insulin instead glargine. The estimated savings of social insur-
ance would be around 224 million HUF on the basis of a Hungarian burden of dia-
betes complication study. CONCLUSIONS: Obesity and weight gain-related aspects 
should be priorized as the main international tendencies showed. It is not only neces-
sary on the policy level, but also in “individual” level in the cost-effectiveness analysis 
as well.
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OBJECTIVES: To examine the association of HbA1c at diagnosis with cost and clini-
cal outcomes in patients with type 2 diabetes (T2D) using three different diabetes 
treatment strategies. METHODS: An existing Monte Carlo diabetes model was used 
to generate demographic and clinical characteristics for 10,000 random patients simu-
lated from the time of T2D diagnosis. Fixed initial HbA1c values were assigned (range: 
7–12%). Input distributions were derived from the literature, with diabetes complica-
tions occurring in: retinopathy, nephropathy, neuropathy, coronary heart disease, and 
stroke. The diabetes-related costs, percentage of patients reaching HbA1c target 
(<7%), complication events, and mortality over 10 years were evaluated using the 
following treatment strategies: (S1) addition of oral antihyperglycemic agents (OHAs) 
at 3-month intervals then starting insulin after 9 months; (S2) addition of OHAs at 
6-month intervals then starting insulin after 2 years; and (S3) addition of OHAs only. 
All treatment strategies began with metformin then sulphonylurea and/or thiazolidin-
edione were added if target was not reached. RESULTS: Diabetes-related costs 
increased as initial HbA1c increased for all three strategies. S1 had the greatest increase 
($5300–$7750) followed by S3 ($4200–$5250) per 1% HbA1c increase from 7% to 
10%. S2 had the smallest rate of increase ($3350–$4950). S3 was the least costly until 
HbA1c exceeded 10%; however, even at HbA1c of 8%, S3 had fewer patients ever 
reaching target (S3 = 79% vs. S1 and S2 = 95% [standard errors, SE < 0.41%]). For 
10,000 patients with initial HbA1c of 9%, the total counts of complications were: S1 
= 4360; S2 = 4126; S3 = 5009 (SE < 67) with mortality rates of 42.5%, 41.9%, and 
45.2% (SE < 0.56%), respectively. CONCLUSIONS: In this model, S2 had the lowest 
complication rates and mortality in patients with T2D. Starting HbA1c affected S1 
cost more than other strategies. Strategies with other treatments or alternative timing 
strategies can be speciﬁ ed and analyzed using this model.
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OBJECTIVES: Response to GH therapy in children with IGHD can be further opti-
mized. To evaluate the economic beneﬁ t of injecting GH with easypod®, an electronic 
autoinjector that objectively monitors drug administration, enabling differentiation of 
poor adherers from low responders. METHODS: A discrete event simulation model 
was developed to model continuous, intermittent (four injections/week) and discontin-
ued GH usage in children with IGHD until ﬁ nal height. a cohort of children (age: 4–12 
years, growth delay: −4.0– −2.5 standard deviation scores [SDS] at baseline) was 
modeled to initiate GH (0.03 mg/kg/day). Annual height gains of 1.2 to 0.8 SDS in year 
1 were assumed to be 30% and 60% lower in each subsequent year of continuous and 
intermittent use, respectively. Baseline nonadherence was 9.3 persons per 100 person-
